ISPOR 15th Annual European Congress - Released Presentations
 
RELEASED PRESENTATIONS

OPENING SPEECH
 

HTA in the European Union – The Way Ahead
Andrzej Rys, MD
, Director of Health Systems and Products, European Commission, Brussels, Belgium

 
PLENARY SESSIONS
 
FIRST PLENARY SESSION:
Converging or Diverging Models of HTA in Europe
Converging or diverging models of HTA in Europe
Wolfgang Greiner, PhD, MSc, Professor & Director, Department of Health Economics and Health Management, University of Bielefeld, Bielefeld, Germany
 
CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE
Jürgen Windeler, MD, Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
 
Convergence or Divergence in Health Technology Assessment Do we need to choose?
Carole Longson, PhD, Director, Centre for Health Technology Evaluation and Executive Director, National Institute of Health & Clinical Excellence (NICE), London, UK
 
HTA in Europe
Jean-Luc Harousseau, MD, President and Chairman of the Board, Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France

SECOND PLENARY SESSION:
International Price Referencing is There A "Right" Way to Perform It?
International price referencing - Is there a right way to perform it?
Kees de Joncheere, PharmD, MBA, MSc, Director, Department of Essential Medicines and Health Products, World Health Organization (WHO), Geneva,
 
International Price Referencing: Is there a "right" way to perform?
Thomas B. Cueni, MSc, Secretary General, Interpharma, Basel, Switzerland
 
Designing Reference Price Systems
Ulrich Kaiser, PhD, MSc, Professor, Department of Business Administration – Entrepreneurship, University of Zürich, Zürich, Switzerland

THIRD PLENARY SESSION:
Fairness First? Social Versus Individual Preferences
Fairness First? Social Versus Individual Preferences
Michael Schlander, MD, PhD, MBA, Professor, Health Care and Innovation Management, University of Heidelberg and Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal), Wiesbaden, Germany
 
Social Preferences in Health Care: A Very Mixed Picture
Erik Nord, PhD, Senior Researcher, Norwegian Institute of Public Health, Oslo, Norway
 
Incorporating Social Preferences Into Economic Evaluation: "Social Cost Utility Analysis"
Jeff Richardson, PhD, Professor, Department of Business and Economics and Foundation Director of the Centre for Health Economics, Monash University, Melbourne, Australia
 
SOCIAL Preferences within the swissHta process
Christian Affolter, PhD, MBA, Head of Foundations, santésuisse, Solothurn, Switzerland

PODIUM AND POSTER PRESENTATIONS
 

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 15th Annual European Congress, see: ISPOR Outcomes Research Digest an electronic database of over 18,700 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 15th Annual European Congress – Berlin, Germany - 2012
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.

 WORKSHOP PRESENTATIONS

(Presentations to be added pending speaker approval)

W1: USING DECOMPOSITION METHODS TO ESTIMATE HETEROGENEITY OF TREATMENT EFFECTS IN RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES
  Using Decomposition Methods to Estimate Heterogeneity of Treatment Effects in Randomized Trials and Observational Studies
William Crown, PhD, Group President, HEOR and Late Phase Research, OptumInsight, Waltham, MA, USA; William H Olson, PhD, Leader, Research and Analysis Strategy, Janssen Pharmaceuticals, Inc., Titusville, NJ, USA
 

W5: UNPLANNED EVIDENCE: IMPLICATIONS OF INVESTIGATOR-INITIATED TRIALS
Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York City, NY, USA; Corinna Sorenson, MPH, MHSA, Research Fellow, European Health Policy, Health & Social Care, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK; Mónica Martín de Bustamante, AB, BE, Managing Director, Europe, Middle East, and Africa, CBPartners, Basel, Switzerland; Cyrus A. Chowdhury, CEO & Managing Director, CBPartners

 

W6: THE ART AND SCIENCE OF EXPERIMENTAL DESIGN - APPLYING THE RECOMMENDATIONS OF THE ISPOR CONJOINT ANALYSIS EXPERIMENTAL DESIGN TASK FORCE
F. Reed Johnson, PhD
, Distinguished Fellow and Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Axel C. Mühlbacher, PhD, Professor for Health Economics and Health Care Management, IGM Institute, Hochschule Neubrandenburg, Neubrandenburg, Germany; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada; John FP Bridges, PhD, AssociateProfessor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

 

W8: IT'S TIME TO REASSESS TRADITIONAL TIME-DEPENDENT REGRESSION METHODS
Christopher M. Blanchette, PhD
, Research Associate Professor, Public Health Sciences, University of North Carolina, Charlotte, NC, USA and Principal, Health Economics & Outcomes Research, IMS Health, Alexandria, VA, USA; Alex Exuzides, PhD, Director, ICON Late Phase & Outcomes Research, San Francisco, CA, USA; Roger Luo, PhD, Director, Advanced Analytics, IMS Health, Plymouth Meeting, PA, USA

 
W9: EARLY MODELLING IN MEDICAL PRODUCT DEVELOPMENT AND MARKET ACCESS
  Early Modelling in Medical Product Development and Market Access
Pierre Sagnier, MD, DEA, MPH, Head, Global Market Access, HEOR, General Medicine, Bayer HealthCare, Berlin, Germany
  A Role for Early Modelling in Technology Development Decisions
Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
 
W10: THE IMPLEMENTATION OF DISINVESTMENT INITIATIVES: A EUROPEAN PERSPECTIVE ON PROGRESS TO DATE
  The implementation of disinvestment initiatives: a European perspective on progress to date
Christian A Gericke, MD, PhD, MPH, MSc, Professor and Deputy Director, PenCLAHRC, Plymouth, Devon, UK
  Disinvestment: the UK experience
Sarah Garner, PhD, BPharm, Associate Director, Research and Development, National Institute of Health and Clinical Excellence (NICE), London, UK
 

W12: PAYER AND HTA PERSPECTIVES ON CLINICAL OUTCOME ASSESSMENTS (COAS)
Erin Tomaszewski, MPH, Clinical Outcomes Research Scientist, Quintiles Outcome, Pittsburgh, PA, USA; Peter Black, MS, Senior Scientist, invivodata Consulting, Pittsburgh, PA, USA; Marta Andreykiv, PharmD, MSc, Senior Consultant, Consulting, Quintiles, Hoofddorp, The Netherlands; Stefan Holmstrom, MSc, Director, HEOR, Astellas Pharma Global Development, Leiderdorp, The Netherlands

 

W13: RETHINKING ANALYSIS OF OUTCOME MEASURES FOR DEMONSTRATING VALUE OF PHARMACEUTICAL PRODUCTS: IMPLICATIONS FOR STUDY DESIGN, PERSONALIZED MEDICINE, AND COMPARATIVE EFFECTIVENESS RESEARCH
Donald E. Stull, PhD, Director Retrospective Data Analysis, RTI Health Solutions, Didsbury, Manchester, UK; Katherine Houghton, BSc, Research Health Outcomes Scientist, RTI Health Solutions, Didsbury, Manchester, UK; Jennifer Petrillo, PhD, Associate Director, Global Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

 

W14: MODELING OF INFECTIOUS DISEASES FOR PREVENTION AND MITIGATION: HOW MODELING HAS INFORMED PUBLIC HEALTH POLICY
Maarten J. Postma, PhD, Professor, Department of Pharmacy, University of Groningen, Groningen, The Netherlands; Kamal Desai, PhD, Research Scientist, Health Economic Modeling and Simulation, United BioSource Corporation, London, UK; Deirdre Hollingsworth, PhD, Research Fellow, MRC Centre for Outbreak Analysis and Modelling, Imperial College London, London, UK; Ruth Chapman, PhD, Research Assistant, Health Economic Modelling and Simulation, United BioSource Corporation, London, UK

 
W15: RETHINKING ANALYSIS OF OUTCOME MEASURES FOR DEMONSTRATING VALUE OF PHARMACEUTICAL PRODUCTS: IMPLICATIONS FOR STUDY DESIGN, PERSONALIZED MEDICINE, AND COMPARATIVE EFFECTIVENESS RESEARCH
  Modeling Health Care from a Systems Perspective
Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada
  What is Versus What Could Be: Incorporating Operations Research Methods in the HEOR Toolkit
William Crown, PhD, Group President, HEOR and Late Phase Research, OptumInsight, Waltham, MA, USA

W16: DON'T FORGET ABOUT THE PATIENT! LISTENING TO PATIENTS AND INVOLVING THEM IN RESEARCH
Elisa Cascade, MBA
, Vice President, MediGuard/Digital Patient Unit, Quintiles, Rockville, MD, USA; Derek C Stewart, BA, Associate Director for Patient & Public Involvement, Clinical Research Networks, National Institute for Health Research, Leeds, UK; Dean Summerfield, MA, DPhil, Vice President, Europe, Quintiles Consulting, Reading, UK

 

W17: ADDITIONAL PATIENT RELATED BENEFITS ARE THE KEY TO PRICE NEGOTIATION IN GERMANY – PRACTICAL EXPERIENCE WITH BENEFIT DOSSIERS AND THE ASSESSMENT PROCESS
Olaf Pirk, MD, PhD
, Director, Olaf Pirk Consult, Nuremberg, Germany; Meriem Hind Bouslouk, PhD, Official Adviser, Drug Department, Federal Joint Committee (G-BA), Berlin, Germany; Frank-Ulrich Fricke, PhD, Professor, Deputy Member of the Arbitration Panel for Drugs, Georg-Simon-Ohm University of Applied Sciences, Nuremberg, Germany

 

W22: USING TIME DEPENDENT ENDPOINTS TO INFORM REIMBURSEMENT DECISION OF CANCER DRUGS IN THE ABSENCE OF MATURE OVERALL SURVIVAL DATA
Jorge Félix, MSc
, Director, Exigo Consultores, Alhos Vedros, Setúbal, Portugal; Anant Murthy, PhD, Executive Director, Global Pricing and Market Access, Celgene Corporation, Boudry, Switzerland; Stefan Michiels, PhD, Biostatistician, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels, Belgium

 

W24: SURVIVAL ANALYSIS IN HTA: IS CURRENT PRACTICE BEST PRACTICE?
John William Stevens, PhD
, Statistician, School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK; Noemi Muszbek, MSc, Research Scientist, United BioSource Corporation, Budapest, Hungary; Martin William Hoyle, MA, PhD, Senior Research Fellow, PenTAG, University of Exeter, Exeter, UK; Edit Remak, MSc, Research Scientist, United BioSource Corporation, Budapest, Hungary

 

W25: ISSUES IN MODELING THE PROGNOSIS AND TREATMENT OF NON-COMMUNICABLE DISEASES USING PATIENT-LEVEL SIMULATION: DO THE GUIDELINES HELP US?
Talitha L. Feenstra, PhD, Health Economist, Epidemiology, University Medical Centre Groningen and RIVM, Groningen, The Netherlands; Christian Asseburg, PhD, MSci, Technical Director, ESiOR Oy, Kuopio, Finland; Annemieke Leunis, MSci, Researcher, Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands; Paul F. M. Krabbe, PhD, Associate Professor, Department of Epidemiology, University of Groningen, Groningen, The Netherlands

 
W26: HETEROGENEITY IN COST EFFECTIVENESS ANALYSIS: IMPLEMENTING METHODS TO REALISE ITS VALUE
  THE VALUE OF HETEROGENEITY (VoH) FOR COST-EFFECTIVENESS SUBGROUP ANALYSIS Methods and application
Manuel Antonio Espinoza, MD, MSc, PhD Student, Centre for Health Economics, University of York, Heslington, York, UK
  The expected value of individualized care methods and application
J. Grutters, PhD, Postdoctoral Researcher, School for Public Health and Primary Care, Maastricht University, Maastricht, Limburg, The Netherlands
 

W29: SAMPLE SIZE ESTIMATION FOR OBSERVATIONAL STUDIES
Terry Alan Cox, MD, PhD, Director, Biostatistics, Real World & Late Phase Research, Quintiles Outcome, Rockville, MD, USA; Eric Gemmen, MA, Senior Director, Biostatistics & Outcomes Research, Real World & Late Phase Research, Quintiles Outcome, Rockville, MD, USA; Mark Nixon, PhD, Director, Biostatistics, Real World & Late Phase Research, Quintiles Outcome, Reading, Berkshire, UK; Pablo Mallaina, MD, MPH, PhD, Senior Medical Manager - Champix, Primary Care BU Europe Canada Australia & NZ (PECANZ), Pfizer, Inc., Madrid, Spain

 
W31: FROM DECISION POINT TO DECISION WINDOW: READINESS FOR A CHANGE OF PARADIGM
  From decision point to decision window: readiness for a change of paradigm
Mondher Toumi, MD, PhD, Professor, Market Access, University Claude Bernard Lyon 1, Lyon, France
ISSUE PANEL PRESENTATIONS

(Presentations to be added pending speaker approval)

 

IP1: ROADMAP OF HTA IN EUROPE - MOVING HTA FORWARD OR JUST STUCK IN TRAFFIC? (ISPOR Invited Issue Panel)
  European Collaboration in HTA - The EUnetHTA work to facilitate the attaining of a sustainable network for HTA
Finn Borlum-Kristensen, MD, PhD, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark
  Road map of HTA in Europe
Gordana Kalan Zivcec, MD, Board Member, Standing Committee of European Doctors (CPME) and President of the Medical Chamber of Slovenia, Ljubljana, Slovenia
IP3: HOW TRANSFERABLE IS CLINICAL EVIDENCE: DOES ONE-SIZE FIT ALL WHEN ASSESSING THE RELATIVE EFFECTIVENESS OF PHARMACEUTICALS IN EUROPE?
  How transferable is clinical evidence: Does one-size fit all when assessing the relative effectiveness of pharmaceuticals in Europe?
Antje Behring, PhD, Desk Officer, Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany; Elisabeth George, PhD, Associate Director, Technology Appraisals, National Institute for Health and Clinical Excellence, London, UK
  Transferability of clinical evidence for RE Assessment
Clare McGrath, PhD, Global Head, HTA Policy, AstraZeneca, Greater Manchester, UK
IP4: HOW IS IQWIG MEETING THE CHALLENGES OF THE NEW GERMAN HEALTH CARE REFORM?
  Early Benefit Assessment and Health Economic Evaluation: Experiences and Challenges under the New Law since Jan 1st, 2011
Andreas Gerber, PhD, MD, Head, Department of Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
  Implementing the new German law on coverage with evidence development (CED) for non-drug interventions
Stefan Sauerland, MD, MPH, Head, Department of Non-Drug Interventions, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
  Challenges for health technology assessment agencies: examples from the UK and Germany
Jos Kleijnen, MD, PhD, Owner, Kleijnen Systematic Reviews, Professor, Systematic Reviews in Health Care, Maastricht University and Clinical Professor, Joanna Briggs Institute, Faculty of Health Sciences, University of Adelaide, York, UK
IP5: POLICY STRATEGIES UNDER AUSTERE CONDITIONS IN EUROPEAN COUNTRIES - DOING LESS WITH LESS AT WHAT COST?
  Doing less with less at what cost / benefit?
László Gulácsi, MD, PhD, Professor, Head, Health Economics and Health Technology Assessment Research Centre, HunHTA, Corvinus University of Budapest, Budapest, Hungary
  THE EXPERIENCE OF GREECE
Mary Geitona, PhD, Professor, School of Social Policy, University of Peloponnese, Korinth, Greece
  POLICY STRATEGIES UNDER AUSTERE CONDITIONS IN EUROPEAN COUNTRIES - DOING LESS WITH LESS AT WHAT COST?
Pedro Pita Barros, PhD, Professor of Economics, Nova School of Business and Economics, Lisbon, Portugal
  the route to increasing value in health care
Niek S. Klazinga, MD, PhD, Professor & Chair, Department of Social Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands and Senior Policy Advisor & Head, Health Care Quality Indicator Programme, Organization for Economic Co-Operation and Development (OECD), Paris, France
IP7: SHOULD MULTIPLE CRITERIA DECISION ANALYSIS (MCDA) REPLACE COST-EFFECTIVE ANALYSIS (CEA)?
  SHOULD MULTIPLE CRITERIA DECISION ANALYSIS (MCDA) REPLACE COST-EFFECTIVE ANALYSIS (CEA)?
Karl Claxton, PhD, Professor of Economics, Centre for Health Economics, University of York, Heslington, York, UK
  MCDA – preferences or utilities? Just a fashion or on the way to more transparency?
Andreas Gerber, PhD, MD, Head, Department of Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
  MCDA for HTA: What factors should we consider including?
Warren Cowell, MSc, HTA Policy, Pfizer, Tadworth, Surrey, UK
IP8: HOW DO YOU ASSESS THE VALUE OF CO-DEPENDENT TECHNOLOGIES?
  How to assess co-dependent technologies
Mira Pavlovic-Ganascia, MD,
Deputy Director for Health Technology Assessment at the Haute Autorité de Santé (HAS), La Plaine Saint Denis, France
  Assessment of co-dependent technologies
Martina Garau, BA, (HONS), MSc, Senior Economist, Office of Health Economics, London, UK; Diego F. Ossa, MD, MSc, Global Head, HEOR MDx, Novartis Pharma AG, Basel, Switzerland
IP9: EVIDENCE GENERATION VIA CONDITIONAL COVERAGE FOR MEDICAL TECHNOLOGIES - WHAT KIND OF EVIDENCE SHOULD BE GENERATED TO SUPPORT ACCESS TO RELEVANT INNOVATIONS?
  Evidence Generation via Conditional Coverage the French Perspective
Annie Chicoye, PhD
, Executive Director for Development, Health Management Institute, ESSEC Business School Paris-Singapore, Cergy-Pontoise, France

IP10: WHICH TO USE? POPULATION BASED OR INDIVIDUAL PATIENT ASSESSMENTS OF VALUE
Stephen James Furniss, BA, Senior Vice President, Market Access, GfK Bridgehead, Melton Mowbray, Leicestershire, UK; Ron Akehurst, BSc, Professor of Health Economics, Dean of School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK; Sue Kilby, MSc, MBA, BPharm, Network Pharmacist South West London Cancer Network, London, UK

IP11: CAN VALUE OF INFORMATION ANALYSIS BE USED ROUTINELY TO INFORM RESEARCH PRIORITIZATION DECISIONS?
  Can Value of Information Analysis be Used Routinely to Inform Research Prioritisation Decisions?
Mark J. Sculpher, MSc, PhD
, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
  Health impact of information Prospects, principles and methods
Karl Claxton, PhD, Professor of Economics, Centre for Health Economics, University of York, Heslington, York
  Using Value of Information in PCORI's Process for Prioritizing Specific Research Topics
Rachael Fleurence, PhD
, Director, Patient-Centered Outcomes Research Insitute (PCORI), Washington, DC, USA
  Can Value of Information be used routinely to inform Research Prioritization Decisions?
Lotte MG Steuten, PhD, Associate Professor, Department of Health Technology and Services Research, University of Twente and Director, Health Economics and Reimbursement, PANAXEA b.v., Twente, The Netherlands

IP12: REFLECTING METHODOLOGICAL AND ENVIRONMENTAL CHANGE IN HTA METHODS: IS THE 2012 NICE GUIDE TO THE METHODS FOR TECHNOLOGY APPRAISAL THE ANSWER?
Paul Tappenden, MSc, Senior Research Fellow, HEDS, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Andreas Gerber, PhD, MD, Head, Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; Elisabeth George, PhD, Associate Director, Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence, Manchester, UK; Stephen Palmer, MSc, Professor, Centre for Health Economics, University of York, York, North Yorkshire, UK

IP14: WILL THE EUNETHTA MODEL FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS WORK?
  Will the EUnetHTA model for Rapid Relative Effectiveness Assessment (REA) of pharmaceuticals work?
Wim Goettsch, PhD
, Project Leader of EUnetHTA WP5 on Relative Effectiveness of Pharmaceuticals and Health Care Insurance Board (CVZ), Diemen, The Netherlands
  Rapid assessment of pazopanib
Marianne Klemp, PhD, Director, The Norwegian Knowledge Centre for the Health Services (NOKC), Oslo, Norway
  WILL THE EUNETHTA MODEL FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS WORK?
Mirjana Huic, MD, MsC, Assistant Director, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia

IP15: CAN THERE BE A COMMON METHODOLOGY FOR COMPARATIVE EFFECTIVENESS IN THE ABSENCE OF RANDOMISED CONTROLLED TRIALS (RCTS)?
Pascale Brasseur, MSc, Reimbursement Director, Cardiovascular Reimbursement and Health Economics, Medtronic International Trading Sàrl, Tolochenaz, Switzerland; Isabelle Durand-Zaleski, PhD, Professor of Medicine, Head of Public Health, Director of the CRU ECO Ile-De-France, Créteil, France; Rod Taylor, MSc, PhD, Professor in Health Services Research, Peninsula Medical School, Exeter, UK; Beth Woods, Oxford Outcomes, Oxford, UK

 
ISPOR FORUMS
(Presentations to be added pending forum host approval)

ECONOMIC ASSESSMENT IN SPAIN: LESSONS TO BE LEARNED AND POSSIBILITIES FOR THE FUTURE
Presented by the ISPOR Spain Regional Chapter

Uso de la evaluaciÓn econÓmica en EspaÑa
Javier Mar Medina, MD, Chief of the Health Management Unit, Hospital Alto Deba, Mondragon, Spain

IMPLEMENTATION OF HTA TO SUPPORT PRICING AND REIMBURSEMENT DECISIONS IN EMERGING MARKET COUNTRIES: MORE ACADEMIC, MORE PRAGMATIC OR "NICER" APPROACH?
Presented by the ISPOR Bosnia-Herzegovina, Hungary, Israel, Republic of Macedonia and Serbia Chapters

IMPLEMENTATION OF HTA TO SUPPORT PRICING AND REIMBURSEMENT DECISIONS IN EMERGING MARKET COUNTRIES: MORE ACADEMIC, MORE PRAGMATIC OR "NICER" APPROACH?
Vlad Zah, Phd (c), Health Economist, Beograd, Serbia

IMPLEMENTATION OF HTA TO SUPPORT PRICING AND REIMBURSEMENT DECISIONS IN EMERGING MARKET COUNTRIES: MORE ACADEMIC, MORE PRAGMATIC OR "NICER" APPROACH?
Tarik Čatić, MSc Pharm, President, ISPOR Bosnia-Herzegovina Regional Chapter, Sarajevo, Bosnia and Herzegovina

IMPLEMENTATION OF HTA TO SUPPORT PRICING AND REIMBURSEMENT DECISIONS IN EMERGING MARKET COUNTRIES: MORE ACADEMIC, MORE PRAGMATIC OR "NICER" APPROACH?
Zoltán Kaló, MSc, MD, PhD, Director, Health Economic Research Center, Department of Health Policy and Health Economics, Associate Professor of Social Sciences Eötvös Loránd University (ELTE) and Founder & CEO, Syreon Research Institute , Budapest, Hungary

Personalized Medicine: How to price it ? How to assess it? Can Public Health System afford it?
Nicky Liebermann, MD, Head of Community Medical Division, Clalit Health Services, Tel-Aviv, Israel

IMPLEMENTATION OF HTA TO SUPPORT PRICING AND REIMBURSEMENT DECISIONS IN EMERGING MARKET COUNTRIES: MORE ACADEMIC, MORE PRAGMATIC OR "NICER" APPROACH? Macedonian perspectives
Ljubica Suturkova, PharmD, PhD, President, ISPOR Republic of Macedonia Regional Chapter and Professor of Faculty of Pharmacy, UKIM, Skopje, Republic of Macedonia

HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL FOR OUTCOMES RESEARCH STUDIES
Presented by ISPOR/AMCP/NPC CER-CI Part1: Interpreting Outcomes Research studies for Health Care Decision Makers Task Forces

HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL FOR MODELING STUDIES
J. Jaime Caro, MDCM, FRCPC, FACP, Chair, CER-CI Interpreting Modeling Studies for Health Care Decision Makers Task Force and Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ and Senior Vice-President, Research, United BioSource Corporation, Lexington, MA, USA

HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL FOR NETWORK META ANALYSIS STUDIES
Jeroen Jansen, PhD
, Chair, CER-CI Interpreting Indirect Treatment Comparison Studies for Health Care Decision Makers Task Force and Vice President, Health Economics & Outcomes Research, MAPI Consultancy, Boston, MA, USA

HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL FOR PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL STUDIES
Marc Berger MD, VP Real World Data and Analytics, Pfizer, New York, NY, USA; Bradley Martin, PhD, RPh, PharmD, Chair, CER-CI Interpreting Retrospective Observational Studies for Health Care Decisions Task Force and Professor & Division Chair, College of Pharmacy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR, USA

HTA AND REIMBURSEMENT SYSTEMS IN RUSSIA AND POLAND: COMMON PROBLEMS AND SOLUTIONS
Presented by the ISPOR Poland, Russia and Russia Far-East Chapters

Russian experience in the evaluation of medical devices
Lyubov Krasnova, MD, PhD, Leading Researcher, Research Department on Health Care Standardization Problems, Moscow Sechenov Medical Academy, Moscow, Russia

Health Technology Assesment in Russia
Pavel Vorobiev, MD, MSc, PhD, President, ISPOR Russia Regional Chapter, Professor, Moscow Sechenov Medical Academy and Head of the Research Department on Health Care Standardization Problems, Moscow, Russia

METHODS OF FINANCING AND DECISION MAKING IN HEALTH CARE IN CENTRAL & EASTERN EUROPE IN TIMES OF LIMITED FUNDS: REVOLUTION OR EVOLUTION?
Presented by the ISPOR Bulgaria, Croatia, and Greece Chapters

Methods of financing and decision making for pharmaceuticals in Bulgaria
Assena Stoimenova, PhD, Associate Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

The Role of Budget Impact Analysis in Decision-Making Processes in Croatia
Josip Čulig, PhD, Professor of Clinical Pharmacology and Toxicology, University JJ.Strossmayer, Medical School Osijek, Osijek, Croatia

MIXED MODES OF PRO DATA COLLECTION: ISPOR PRO TASK FORCE FINAL RECOMMENDATIONS
Presented by the ISPOR PRO Mixed Modes Task Force

Mixing Modes of Patient -Reported Outcomes Data Collection in Clinical Trials: Recommendations
Sonya Eremenco MA, ePRO Manager, United BioSource Corporation, Bethesda, MD, USA

HEALTH TECHNOLOGY ASSESSMENT IN A RESOURCE CONSTRAINED SETTING: REAL CHALLENGES FACING ASIA
Presented by the ISPOR Asia Consortium

How to play the role of HTA in evidence-based decision making in China?
Wen Chen, PhD, Professor & Deputy Dean, School of Public Health, Fudan University, Shanghai, China

Hong Kong and Malaysia – HTA Development and Challenges Ahead
Kenneth KC Lee, BSc (Pharm), MPhil, PhD, Professor of Pharmacy and Head of Pharmacy Programme, School of Medicine and Health Sciences, Monash University, Kuala Lumpur, Malaysia

HTA in Thailand
Surachat Ngorsuraches PhD, RPh, Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand

Health Technology Assessment in a Resource Constrained Setting: Real Challenges Facing Asia
Bong-Min Yang, PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

PATIENTS AND THEIR ROLE IN MARKET ACCESS: WHERE IS THE PLACE AND WHAT IS THE ROLE OF PATIENTS IN REIMBURSEMENT SYSTEMS?
Presented by the ISPOR Romania, Serbia and Slovakia Chapters

PATIENTS AND THEIR ROLE IN MARKET ACCESS WHERE IS THE PLACE AND WHAT IS THE ROLE OF PATIENTS IN REIMBURSEMENT SYSTEMS?
Dominik Tomek, PharmD, MPH, PhD, President, ISPOR Slovakia Regional Chapter and Faculty of Pharmacy, Comenius University and Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia

PATIENTS AND THEIR ROLE IN MARKET ACCESS: WHERE IS THE PLACE AND WHAT IS THE ROLE OF PATIENTS IN REIMBURSEMENT SYSTEMS? - Romania -
Paul Radu, MD, PhD, Market Access Manager, Roche Romania, Bucharest, Romania

THE SOCIO-ECONOMIC IMPACT OF HEALTH CARE COST-CONTAINMENT MEASURES DURING ECONOMIC CRISIS IN THE EUROPEAN UNION (EU)
Presented by the ISPOR Bulgaria, Czech and Greece Chapters

THE SOCIO-ECONOMIC IMPACT OF HEALTH CARE COST-CONTAINMENT MEASURES DURING ECONOMIC CRISIS IN BULGARIA
Guenka Petrova, MPharm, MEcon, PhD, DSc, President, ISPOR Bulgaria Regional Chapter and Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

THE SOCIO-ECONOMIC IMPACT OF HEALTH CARE COST-CONTAINMENT MEASURES DURING ECONOMIC CRISIS IN CZECH REPUBLIC
Jana Skoupa, MD, MBA, 1st Medical Faculty Member, Medical Data Center, Charles University, Prague, Czech Republic

EDUCATIONAL SYMPOSIA

(Presentations to be added pending symposia host approval)

DO WE NEED INNOVATIVE MEASURES TO MEASURE INNOVATION?
(Sponsored by GalbraithWight)

New options to consider for delivering and valuing innovation
Colin Wight, Chief Executive, GalbraithWight, Polegate, UK

Scottish Medicines consortium- what we do now and how could we accommodate innovation concepts?
Ailsa Brown, Lead Health Economist, Scottish Medicines Consortium, Glasgow, UK

How do we currently measure innovation? Do we need to do more?
Nic Brereton, BSc., Health Economist & Managing Director, BresMed Health Solutions LTD, Sheffield, UK

New Research for Future Approaches to Measuring and Valuing Health
(Sponsored by the EuroQol Group)
Nancy Devlin, PhD, Director of Research, Office of Health Economics, London, UK; Ben van Hout, PhD, Professor, Department of Health Economics, University of Sheffield, Sheffield, UK; Andrew Lloyd, PhD, Vice President, Patient Reported Outcomes, Oxford Outcomes, Oxford, UK; John Brazier, PhD, Professor, HEDS, ScHARR, University of Sheffield, Sheffield, UK

EFFECTIVE COMMUNICATION WITH FEDERAL AUTHORITIES FOR SCIENTIFIC ADVICE EARLY IN PRODUCT DEVELOPMENT
(Sponsored by RTI)

Anne Heyes, MBA, Head, Market Access and Outcomes Strategy - Europe, RTI Health Solutions, Manchester, UK; Michael Kulig, MD, PhD, MPH, Scientific Advisor, Medical Consultancy Department, Federal Joint Committee, Berlin, Germany; Leeza Osipenko, PhD, Senior Scientific Adviser, Scientific Advice Programme, Centre for Health Technology Evaluation, NICE, London, UK; Fredrik Nilsson, PhD, Senior Health Economist, Dental and Pharmaceutical Benefits Agency, Reimbursement Applications Unit, Stockholm, Sweden; Doreen McBride, PhD, Senior Director, Health Economics - Germany, RTI Health Solutions, Berlin, Germany


15th Annual European Congress Main Page